treatment

STAT5 Protein Complex Implicated in MS Autoimmunity in Mice

A four-protein complex, or tetramer, of the protein STAT5 is involved in the development of multiple sclerosis (MS)-like autoimmune disease in mice, a new study shows. The findings point to this protein complex and its signaling pathway as a potential treatment in MS and other autoimmune conditions, scientists noted.

Top 10 Multiple Sclerosis Stories of 2021

Multiple Sclerosis News TodayĀ brought you daily coverage of the latest scientific research, advances in treatment, and clinical trials related to multiple sclerosis (MS) throughout 2021. We look forward to continuing to be a resource for the MS community in 2022. Here are the Top 10 most-read articles of…

Gilenya Started Earlier in RRMS Disease Course in Recent Years

People with relapsing-remitting multiple sclerosis (RRMS) have switched to treatment with Gilenya (fingolimod) at an earlier stage in their disease in recent years, compared to individuals who switched to the treatment around the time it became available, a new study indicates. The findings suggest “an increased experience in…

#AANAM ā€“ Research Focuses on Measuring Therapeutic Lag

Editorā€™s note: TheĀ Multiple Sclerosis News TodayĀ team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, held April 17ā€“22. GoĀ hereĀ to read the latest stories from the conference. A novel method to calculate how long it takes therapies for multiple sclerosis (MS) to become fully effective…

MS Patient Donates $700,000 to Ochsner MS Work

Desi Harrison, a multiple sclerosis (MS) patient and president of the nonprofit MS Warriors for a Cause, has donated $700,000 to support the Ochsner Neuroscience Institute. The funds will help support research and care at theĀ Ochsner Multiple Sclerosis Center to ensure that patients ā€” like Harrison, who…

Pregnancy Does Not Change Long-term Course of MS, New Data Suggest

Pregnancy does not lead to long-term changes in the disease course ofĀ multiple sclerosisĀ (MS), new research suggests. This work, which emphasizes the importance of careful data analysis, supports studies disputing previous beliefs that pregnancy worsened or lessened the long-term disease course of MS. The findings were presented by Mar Tintore,…

Need to Know: 21st-century Medicine Models

Editor’s note: “Need to Knowā€ is a series inspired by common forum questions and comments from readers. Have a comment or question about MS? Visit our forum. This week’s question is inspired by the forum topicĀ “Do We Need a Personalized Approach to Treating MS?” from May 23,…

Michiganā€™s Memorial Healthcare First in US to Test NfL in MS Patients

Memorial Healthcare Institute for Neurosciences and Multiple SclerosisĀ announced it will become the first U.S. hospital to test a nerve cell-derived component known as neurofilament light chain (NfL) in multiple sclerosis (MS) patients. Led by the Owosso, Michigan, hospitalā€™s chief of neurology and MS director, Rany Aburashed, DO,…

NeurologyLive Launches Series of Educational Videos About MS

NeurologyLiveĀ has launched a series of educational videosĀ intended to provide an overview of the diagnositic methods and treatment options available toĀ multiple sclerosis (MS) patients. The video series, “Advances in the Diagnosis and Management of Multiple Sclerosis,” also will include future perspectives on upcoming MS therapies,…

MS Treatment Decisions Can Cause a ‘Gambler’s Dilemma’

One of the toughest decisions facing someone with MS is whether to begin treatment with a disease-modifying therapy (DMT). Equally tough, I think, is deciding which DMT road to travel ā€” because there are three roads that can be followed. One path starts you on a simple, first-level medication. These…

A Look Inside MS Marketplace Projections

Do you ever stop and ponder the value of MS drugs? Iā€™m not talking about if they work and the ways they improve our lives. Iā€™m thinking of the COST of them and what their pricing means to investors. I get several market analysis reports on the pharmaceutical industry,…

Five Research Projects Totaling $38 Million to Compare Effectiveness of MS Treatment Strategies

The Patient-Centered Outcomes Research InstituteĀ has awarded $38 million in grants for five projects that compare the effectiveness of different multiple sclerosis treatment strategies. A key aim of the research is to improve knowledge about the therapiesĀ to help doctors and patients choose the healthcare option that best meets patients’ needs.Ā The…

Nurse Advocates for Shared Decision-Making to Treat MS

Shared decision-making between patients and their doctors and healthcare providers was considered a critical step in the process of treatingĀ multiple sclerosis (MS), according toĀ an article published in the journal Practical Neurology. The article ā€œShared Decision-making in Multiple Sclerosis Managementā€ was written by Amy Perrin Ross, a board-certified…

Ocrevus Market Entry Already Changing Dynamics in MS Treatment Choices, Spherix Analysis Suggests

Multiple sclerosis (MS) patients are largely moving away from injectable drugs and towards oral treatments when they switch from first to second-line MS therapies. ButĀ that might change with theĀ introduction of Ocrevus (ocrelizumab), whichĀ has becomeĀ the drug of choice for manyĀ neurologists advising patients on drug switches. The real-world analysis by…

RMS Patient Using Ocrevus in Trial: ‘I Feel Great’

Pamela Arterbridge is one of 70 people at Ohio State Universityā€™s Multiple Sclerosis Center taking part in the open-label part of aĀ clinical trial for ocrelizumab, nowĀ best known asĀ Ocrevus.Ā  She is a patient of Dr. Michael Racke, who is a pioneer in the field of B-cell treatmentsĀ for MS,…

Pills, Shots or Infusions for Your MS?

Oral multiple sclerosis meds appear, more and more, to be the first choice of patients who are just beginning to receive an MS treatment. A recent report by the independent marketing research firmĀ Spherix Global Insights shows thatĀ oral disease-modifying therapies captured a significantly higher…

Lemtrada for My MS: First Month Report

It’s been a month since I completed my first round of Lemtrada infusions, so it’s time to bring everyone up to date on how things are going. I was told to expect a roller coaster of side effects. I’m pleased to say that, at least so far, it’s…